Life Sciences

  • July 08, 2025

    Chinese Man Arrested Over COVID Data Theft, Law Firm Hack

    Federal agents have arrested a Chinese citizen to face criminal charges for his alleged role in the Microsoft "HAFNIUM" cyberattack in which the People's Republic of China allegedly directed him and a co-conspirator to hack email accounts at a law firm and a Texas university to steal crucial COVID-19 vaccine information.

  • July 08, 2025

    Omnicare, CVS Tab In FCA Case Increases To $949M

    A New York federal judge on Monday raised a False Claims Act judgment against Omnicare and CVS to a combined $949 million following a jury's finding that they submitted millions of false prescription claims for long-term care patients.

  • July 08, 2025

    Trump Declares 50% Copper Tariff, Floats 200% Pharma Tariff

    President Donald Trump announced Tuesday that he will impose a new 50% tariff on copper imported into the U.S., while also raising the possibility of imposing a 200% tariff on pharmaceuticals.

  • July 08, 2025

    Teva Challenge To J&J Antipsychotic Patent Fails At Fed. Circ.

    The Federal Circuit on Tuesday rejected Teva Pharmaceuticals USA Inc.'s challenge to the validity of claims in a Johnson & Johnson unit's patent covering a lucrative schizophrenia drug, disagreeing with the generic-drug maker that one of the patent's claims should be presumed obvious.

  • July 08, 2025

    Mylan Securities Class Action Over W.Va. Plant Will Proceed

    A Pennsylvania federal judge on Tuesday denied a win for former pharmaceutical company Mylan NV in a proposed shareholder class action accusing the company of manipulating quality control tests at a West Virginia plant, saying the plaintiff has met the burden of showing a link between misrepresentations and financial losses.

  • July 08, 2025

    Biosimilars Industry Group Backs Interchangeability Bill

    The current law on how biosimilars are deemed interchangeable or not with their name-brand biologic equivalents has led to public confusion over how safe biosimilars are, a coalition of healthcare industry groups told lawmakers in a letter Monday.

  • July 08, 2025

    Anoxia Says Alembic's Blood Clot Catheter Infringes Patents

    Anoxia Medical Inc. commenced a patent infringement suit in California federal court Monday against its competitor Alembic LLC, accusing Alembic of ripping off Anoxia's novel technology for its endovascular "Slinky®" catheter invention that efficiently removes blood clots from the human body.

  • July 08, 2025

    4th Circ. Revives Medical Device Co.'s Claim In Contract Suit

    The Fourth Circuit on Tuesday revived a medical device maker's breach of contract claim alleging a company it hired to manage its patents globally overcharged for services, sending the case back to a Virginia federal court.

  • July 08, 2025

    Wash. Law Firm Settles Investors' Suit Over $1M Escrow Loss

    A Washington-based law firm has settled a lawsuit in which investors accuse it of losing $1 million in escrow funds intended as a security deposit on a medical supplies purchase, the parties have informed a federal judge just weeks before the scheduled trial date.

  • July 08, 2025

    Masimo Criticizes Bid To DQ Quinn Emanuel In Payout Suit

    Masimo Corp. is fighting a bid by its former CEO Joe Kiani to disqualify Quinn Emanuel Urquhart & Sullivan LLP from representing the medical technology company in Delaware Chancery Court litigation over Kiani's quest for a $450 million payout.

  • July 08, 2025

    Medical Co. Wants High Court To Review Rushed Patent Case

    A medical device maker has asked the U.S. Supreme Court to hear it out on claims that a North Carolina federal judge rushed the case to trial and violated the Fifth Amendment right to due process by shortening the amount of time for discovery.

  • July 08, 2025

    Vaxart Investors Can Pursue Suit Over COVID Vax Claims

    A California federal judge declined to grant an early win to the onetime controlling shareholder of Vaxart in an investor suit alleging it dumped stock at inflated prices following deceptive headlines about the biotechnology company's ability to produce a COVID-19 vaccine.

  • July 08, 2025

    High Court Allows Trump's Gov't Cuts And Restructuring

    The U.S. Supreme Court on Tuesday ruled the Trump administration can move forward with its plans for large-scale layoffs and reorganizations at various federal departments and agencies, lifting a California federal judge's order that had paused the efforts while a legal challenge continues.

  • July 07, 2025

    Annoyed Fed. Circ. Judge Unsure Where To Land In Drug Row

    An irascible Federal Circuit judge chewed out both sides of the aisle Monday morning during arguments over a generic endocrine disorder drug, and although she accused one attorney of "beating a straw man to death," the judge said she still wasn't sure how she would decide the appeal.

  • July 07, 2025

    Fed. Circ. Digs Into Domestic Industry For Apple Watch Appeal

    A Federal Circuit panel on Monday struggled with how to meet domestic industry requirements needed for the U.S. International Trade Commission to issue import bans, as it evaluated the agency's high-profile decision to keep certain Apple Watches out of the U.S.

  • July 07, 2025

    Pregnant Doc, Medical Orgs. Sue To Block RFK's Vax Directive

    A pregnant doctor who fears she will be denied a COVID-19 vaccination, along with a coalition of medical associations, sued Health and Human Services Secretary Robert F. Kennedy Jr. in Massachusetts federal court on Monday challenging his directive recommending against the shot for pregnant women and children.

  • July 07, 2025

    Fitch Even Fights Bid To Toss Prenatal Test Patent Suit

    Fitch Even Tabin & Flannery LLP is urging an Illinois federal court not to toss its suit seeking a declaration that the co-founder of a former client isn't the inventor behind a prenatal test patent, contesting her argument that the firm lacks standing to sue.

  • July 07, 2025

    Calif. Fails To Pause 23andMe's Sale During Appeal

    A Missouri bankruptcy judge on Monday refused California's request that genetic testing company 23andMe Holding Co.'s $305 million Chapter 11 sale be tabled while the Golden State seeks an appeal.

  • July 07, 2025

    Kirkland-Led Zenyth Partners Raises $375M For Latest Fund

    Kirkland & Ellis LLP-advised private equity shop Zenyth Partners on Monday announced that it closed its second flagship fund after securing $375 million in capital commitments, which will be used to invest in healthcare services-focused companies.

  • July 07, 2025

    Ex-Leerink Banker Can't Get Redo On Unpaid Bonuses Claim

    A Massachusetts federal judge declined on Monday to rethink partially tossing a former Leerink Partners employee's suit alleging she was cheated out of millions of dollars in bonuses, rejecting the worker's argument that new evidence should change the court's mind.

  • July 07, 2025

    USPTO Ups Number Of Prioritized Patent Applications

    The U.S. Patent and Trademark Office is raising the number of applications it can accept each year for a prioritized patent examination to 20,000.

  • July 07, 2025

    P&G Beats False Ad Suit Over 'Pure Cotton' Tampax, For Good

    The Procter & Gamble Co. permanently beat a proposed class action alleging that it omits the presence of organic fluorine in its Tampax products, after a California federal judge again rejected the plaintiff's testing method for detecting forever chemicals, ruling Monday that the latest iteration of the suit continued to rest on flawed testing.

  • July 07, 2025

    Catching Up With Delaware's Chancery Court

    In Delaware in the past week, a vice chancellor awarded just $1 in damages to a China-tied company looking to secure a $50 million stake in SpaceX while also slamming the fund's manager for acting "insincerely," Tyson Foods won $55 million in damages in a suit claiming the owner of two poultry rendering plants Tyson acquired hid that it relied on a "disfavored" practice of recovering "unappetizing remnants of butchered chickens," and a suit over a one-site bank's 11-aircraft fleet was moved into the discovery phase.

  • July 07, 2025

    J&J Unit Looks To Wipe Out $442M Catheter Antitrust Loss

    Johnson & Johnson health tech unit Biosense Webster has asked a California federal court to throw out Innovative Health's $442 million trial win in a case accusing Biosense of conditioning product support for its cardiac mapping systems on the purchase of cardiac catheters.

  • July 03, 2025

    Stewart Drops Mixed Bag Of Discretionary Denial Rulings

    Acting U.S. Patent and Trademark Office Director Coke Morgan Stewart has released 24 more discretionary denial decisions, more than half of which she cleared challenges to move forward through the Patent Trial and Appeal Board process.

Expert Analysis

  • When Legal Advocacy Crosses The Line Into Incivility

    Author Photo

    As judges issue sanctions for courtroom incivility, and state bars advance formal discipline rules, trial lawyers must understand that the difference between zealous advocacy and unprofessionalism is not just a matter of tone; it's a marker of skill, credibility and potentially disciplinary exposure, says Nate Sabri at Perkins Coie.

  • Should Patent Disputes Be Filed In The ITC Or UPC?

    Author Photo

    When companies must choose between initiating patent litigation in the U.S. International Trade Commission or the European Union's Unified Patent Court, the ITC may offer a few distinct advantages, but ultimately the decision requires consideration of case-specific factors, say attorneys at White & Case.

  • Opinion

    NJ Should Align With Federal Rule On Expert Testimony

    Author Photo

    The time is right to amend Rule 702 of the New Jersey Rules of Evidence to align it with the recently amended Rule 702 of the Federal Rules of Evidence and clarify the standard for admissibility of expert testimony, says Timothy Freeman at Tanenbaum Keale.

  • 2 NY Rulings May Stem Foreign Co. Derivative Suits

    Author Photo

    In recent decades, shareholders have challenged the internal affairs doctrine by bringing a series of derivative actions in New York state court on behalf of foreign corporations, but the New York Court of Appeals' recent rulings in Ezrasons v. Rudd and Haussmann v. Baumann should slow that trend, say attorneys at Cleary.

  • Recent Reports Shed Light On Section 340B's Effectiveness

    Author Photo

    Recent analyses of the Section 340B program's effectiveness in helping patients afford drugs in Minnesota reinforce concerns about the program's lack of transparency and underscore the need for further evaluation of whether legislative reform should be enacted, say William A. Sarraille at the University of Maryland, and Andrée-Anne Fournier and Molly Frean at Analysis Group.

  • Opinion

    Congress Should Pass IP Reform, Starting With 3 Patent Bills

    Author Photo

    Congress is considering a trio of bipartisan bills to fix patent law problems that have cropped up over the past two decades, and it shouldn't stop there — addressing two other intellectual property issues is critical for America's economy, says retired Judge Kathleen O'Malley at the Council for Innovation Promotion.

  • Class Standing Issues Still Murky After Justices Punt LabCorp

    Author Photo

    While litigants and district courts had hoped the U.S. Supreme Court's ruling in LabCorp v. Davis would provide much-needed clarity on the interplay between Article III standing and class certification, the court's failure to rule on the issue leaves disagreement, confusion and uncertainty for stakeholders, says Erica Rutner at Cozen O'Connor.

  • When Reshoring, IP Issues Require A Strong Action Plan

    Author Photo

    With recent headlines highlighting tariffs as high as 3,521%, more firms will contemplate reshoring manufacturing to the U.S., and they will need to consider important intellectual property issues as part of this complex, expensive and lengthy undertaking, say attorneys at Norton Rose.

  • Series

    Volunteering At Schools Makes Me A Better Lawyer

    Author Photo

    Speaking to elementary school students about the importance of college and other opportunities after high school — especially students who may not see those paths reflected in their daily lives — not only taught me the importance of giving back, but also helped to sharpen several skills essential to a successful legal practice, says Guillermo Escobedo at Constangy.

  • 5 Open Questions About FDA's AI-Assisted Review Plans

    Author Photo

    The U.S. Food and Drug Administration recently touted the completion of a generative artificial intelligence program for scientific reviewers and plans for agencywide deployment to speed up reviews of premarket applications, but there is considerable uncertainty surrounding the tools' ability to protect trade secrets, avoid bias and more, say attorneys at King & Spalding.

  • Prospects And Challenges For Expert Evidence At The UPC

    Author Photo

    Expert testimony on economic or damages-related issues will likely play a larger part in Unified Patent Court proceedings in the near future, potentially presenting unique challenges for experts, counsel and judges alike, say analysts at Charles River.

  • Attacks On Judicial Independence Tend To Manifest In 3 Ways

    Author Photo

    Attacks on judicial independence now run the gamut from gross (bald-faced interference) to systemic (structural changes) to insidious (efforts to undermine public trust), so lawyers, judges and the public must recognize the fateful moment in which we live and defend the rule of law every day, says Jim Moliterno at Washington and Lee University.

  • Series

    Law School's Missed Lessons: Appreciating Civil Procedure

    Author Photo

    If you’re like me, law school’s often complex and theoretical approach to teaching civil procedure may have contributed to an early struggle with the topic, but when seen from a practical perspective, new lawyers may find they enjoy mastering these rules, says Chloe Villagomez at Foster Garvey.

  • Calif. Bar Exam Fiasco Shows Why Attys Must Disclose AI Use

    Author Photo

    The recent revelation that a handful of questions from the controversial California bar exam administered in February were drafted using generative artificial intelligence demonstrates the continued importance of disclosure for attorneys who use AI tools, say attorneys at Troutman.

  • In 2nd Place, Va. 'Rocket Docket' Remains Old Reliable

    Author Photo

    The U.S. District Court for the Eastern District of Virginia was again one of the fastest civil trial courts in the nation last year, and an interview with the court’s newest judge provides insights into why it continues to soar, says Robert Tata at Hunton.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.